Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Various symptoms indicate chronic myelogenous leukemia (CML) has progressed from one phase to another. These include an increase in leukemia cells, a change in a person’s platelet count, and worsening ...

An unusual white blood cell count can be a sign of chronic myeloid leukemia (CML), a type of blood cancer. CML can affect the balance of white blood cells in the blood and cause them to function ...

Chronic myelomonocytic leukemia (CMML) and chronic myeloid leukemia (CML) are two types of cancers that affect the blood and bone marrow. In both types, certain blood cells multiply out of control.

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib. Patients with chronic myelogenous leukemia (CML ...

Novartis is in Chicago for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and has brought along an interactive experience for the weekend. The Swiss drugmaker is rolling out its ...

76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% ...

At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with blast-phase chronic myeloid leukemia (CML) using data from a multi-institution ...

David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of financial accounting, corporate and individual tax planning and preparation, and investing and retirement planning.